Zinc or Multiple Micronutrient Supplementation to Reduce Diarrhea and Respiratory Disease in South African Children: A Randomized Controlled Trial

Kany-Kany Angelique Luabeya1, Nontobeko Mpontshane3, Malanie Mackay1, Honorine Ward4, Inga Elson5, Meera Chhagan6,7, Andrew Tomkins8, Jan Van den Broeck9, Michael L. Bennish9,*

1 Africa Centre for Health and Population Studies, University of KwaZulu Natal, Somkhele, South Africa, 2 Church of Scotland Hospital, Tugela Ferry, South Africa, 3 Department of Medical Microbiology, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa, 4 Division of Geographic Medicine and Infectious Diseases, Tufts-New England Medical Centre, Boston, Massachusetts, United States of America, 5 Department of Chemical Pathology, University of KwaZulu-Natal, Durban, South Africa, 6 Department of Paediatrics and Child Health, University of KwaZulu-Natal, Durban, South Africa, 7 Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts, United States of America, 8 Centre for International Child Health, University of London, London, United Kingdom, 9 Tropical Medicine Research Institute, University of the West Indies, Kingston, Jamaica, 10 Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom

Background. Prophylactic zinc supplementation has been shown to reduce diarrhea and respiratory illness in children in many developing countries, but its efficacy in children in Africa is uncertain. Objective. To determine if zinc, or zinc plus multiple micronutrients, reduces diarrhea and respiratory disease prevalence. Design. Randomized, double-blind, controlled trial. Setting. Rural community in South Africa. Participants. Three cohorts: 32 HIV-infected children; 154 HIV-uninfected children born to HIV-infected mothers; and 187 HIV-uninfected children born to HIV-uninfected mothers. Interventions. Children received either 1250 IU of vitamin A; vitamin A and 10 mg of zinc; or vitamin A, zinc, vitamins B1, B2, B6, B12, C, D, E, and K and copper, iodine, iron, and niacin starting at 6 months and continuing to 24 months of age. Homes were visited weekly. Outcome Measures. Primary outcome was percentage of days of diarrhea per child by study arm within each of the three cohorts. Secondary outcomes were prevalence of upper respiratory symptoms and percentage of children who ever had pneumonia by maternal report, or confirmed by the field worker. Results. Among HIV-uninfected children born to HIV-infected mothers, median percentage of days with diarrhea was 2.3% for 49 children allocated to vitamin A; 2.5% in 47 children allocated to receive vitamin A and zinc; and 2.2% for 46 children allocated to multiple micronutrients (P = 0.852). Among HIV-uninfected children born to HIV-uninfected mothers, median percentage of days of diarrhea was 2.4% in 56 children in the vitamin A group; 1.8% in 57 children in the vitamin A and zinc group; and 2.7% in 52 children in the multiple micronutrient group (P = 0.857). Only 32 HIV-infected children were enrolled, and there were no differences between treatment arms in the prevalence of diarrhea. The prevalence of upper respiratory symptoms or incidence of pneumonia did not differ by treatment arms in any of the cohorts. Conclusion. When compared with vitamin A alone, supplementation with zinc, or with zinc and multiple micronutrients, did not reduce diarrhea and respiratory morbidity in rural South African children. Trial Registration. ClinicalTrials.gov NCT00156832

Citation: Luabeya KA, Mpontshane N, Mackay M, Ward H, Elson I, et al (2007) Zinc or Multiple Micronutrient Supplementation to Reduce Diarrhea and Respiratory Disease in South African Children: A Randomized Controlled Trial. PLoS ONE 2(6): e541. doi:10.1371/journal.pone.0000541

INTRODUCTION

Micronutrient deficiencies are common in children in developing countries, including children in South Africa.[1–3] Zinc deficiency is especially thought to be associated with an increased susceptibility to infection, and a greater severity of disease when infection occurs.[4] Zinc is now recommended by the WHO for the treatment of children with diarrhea in developing countries,[5] but its role for the prophylaxis of infection is less certain.

Studies in Asia and Latin American have generally found that prophylactic zinc reduces the incidence, duration and severity of diarrhea and pneumonia episodes when given to infants and young children.[6] Few studies have been conducted of prophylactic administration of zinc in Africa,[7,8] which differs, especially from Asia, in diet and patterns of growth in children,[9] and in the burden of infectious diseases, especially HIV. Because micronutrient deficiencies are seldom isolated to a single micronutrient, there have also been efforts to provide supplements containing an array of micronutrients.[1]

In KwaZulu-Natal, where this study was conducted, antenatal HIV prevalence is 39%.[10] Children with HIV infection are known to be at high risk of infection and poor nutrition and growth,[11] and those born to HIV-infected mothers but not

Academic Editor: Jose M. Belizan, Institute of Clinical Effectiveness and Health Policy, Argentina

Received May 3, 2007; Accepted May 9, 2007; Published June 27, 2007

Copyright: © 2007 Luabeya et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by grants from the United States National Institute of Health (1 U01 AI45508-01, 1 K24 AI/HD01671-01, D43TW05572-01 to Dr. Bennish and Welcome 62925 to Dr. Bennish and Welcome 063009 to Dr. Van den Broeck. The National Institutes of Health provided training in good clinical practice to study staff, arranged for the study to be monitored by a contract research organization to ensure compliance with good clinical practice, and established a Data Monitoring and Safety Board to oversee the trial. The sponsor for the study was the host institution, the Africa Centre for Health and Population Studies, which gave discretion in the investigative team in study design, data analysis, manuscript preparation, and decisions on manuscript submission and publication.

Competing Interests: The authors have declared that no competing interests exist.

* To whom correspondence should be addressed. E-mail: mbennish@hotmail.com
themselves infected may be at increased risk of nutritional deficiencies because of parental illness.

METHODS
The protocol for this trial and supporting CONSORT checklist are available as supporting information; see Checklist S1 and Protocol S1.

Study area
The study was conducted in northern KwaZulu-Natal Province, South Africa. Median household income in the area is one-half the national average, 80% of the population lives below the national poverty line, and unemployment is 75%.[12] There is little subsistence farming in this area despite 98% of households being defined as rural, and food insecurity within households is common.[12] Most infants receive both breast and complementary feeding from early infancy,[13] and the diet is known to be deficient in micronutrients.[14]

Participants
Children were enrolled into the study by nurses at five government primary health care clinics. Study subjects were recruited from children coming to the clinics for routine visits, from households identified as having potentially eligible children based on surveillance conducted by the Africa Centre Demographic Information System, and from children enrolled at birth in an observational study of the determinants of mother-to-child transmission of HIV.

Children eligible for study were four to six months old. Children were excluded from study if they were: less than 60% of median weight-for-age using United States National Center for Health Statistics standards,[15] had nutritional edema; had received vitamin or micronutrient supplements in the previous month; had diarrhea for more than seven days at the time of study enrollment; or were enrolled in another study of a clinical intervention.

To maintain community blinding to the HIV status of women enrolled in the study, we enrolled children in any cohort which reached targeted enrollment before enrollment was completed in other cohorts, provided them only their initial two weeks of supplement, and did not include them in the analysis.

Ethics and study monitoring
The study was approved by the Ethics Review Committee of the University of KwaZulu-Natal and the Institutional Review Board of Tufts-New England Medical Center. Before initiation the study was presented to the Community Advisory Board of the Africa Centre for their review and advice, and interim reports on study progress were provided to this Advisory Board. The study was also monitored by a Data Monitoring and Safety Board established by the NIH. Written informed consent to participate in the study, and to do HIV testing on both the mother and child, was obtained from all mothers whose children participated in the study.

Intervention
The three treatment arms were: vitamin A alone; vitamin A plus zinc; and vitamin A, zinc and multiple micronutrients. All supplements were given daily at home from entry into the study until 24 months of age. Vitamin A was given as the comparator regimen, rather than placebo, because the South African Department of Health guidelines recommend routine three-monthly vitamin A supplementation for children and clinics did not consistently provide vitamin A to children. Thus each of the three tablet formulations contained 1250 IU of vitamin A. Two of the three tablet formulations contained 10 mg of zinc as zinc gluconate. The multiple micronutrient tablets were similar to those used in recent international trials of multiple micronutrient supplementation,[16] and in addition to vitamin A and zinc contained: 0.5 mg each of vitamins B1, B2 and B6; 0.9 μg vitamin B12; 35 mg vitamin C; 5 μg vitamin D3; 6 mg vitamin E; 10 μg vitamin K1; 0.6 mg copper as cupric gluconate; 150 μg folate; 50 μg iodine; 10 mg iron as ferrous fumarate; and 6 mg niacin. The supplements were manufactured as tablets by Hersil Ltd. ( Lima, Peru) and packaged in blister packs of seven tablets. All three formulations were similar in color, taste, appearance and size. Because of a delay in shipment, 243 children enrolled in the study did not receive supplements for 11 weeks in 2005.

Objectives
To study objective was to determine if zinc, or zinc plus multiple micronutrients, would reduce diarrhea and respiratory disease prevalence. We hypothesized that both zinc, and zinc plus multiple micronutrients, would reduce diarrhea and respiratory disease prevalence and examined their efficacy in a randomized controlled trial in children 6–24 months of age born to both HIV-infected and HIV-uninfected mothers.

Study Outcomes
The primary study outcome was the percentage of days of diarrhea per child compared between study arms within each of the three cohorts. Secondary diarrheal disease outcomes were measures of the severity of diarrhea (duration of episodes, maximum number of stools during an episode, episodes lasting 14 or more days, diarrhea episodes with blood in the stool, and clinic visits for diarrheal episodes) and the distribution of diarrheal morbidity (proportion of children who ever had diarrhea and number of episodes per child). Respiratory disease outcome measures were the percentage of weeks of upper respiratory symptoms per child, the percentage of children who ever had pneumonia by maternal report, and the percentage of children with pneumonia confirmed by the field worker.

Study definitions
Diarrhea was considered to be present on any day the stool was more frequent or looser than normal or the stool contained water or blood. An episode of diarrhea terminated on the last day of diarrhea that was followed by two consecutive days without diarrhea. Blood was considered present in stool if reported by the mother. Upper respiratory tract infection was defined as the history (or presence during the field worker visit) of cough or runny nose. Because field workers asked about the occurrence of these signs since the last visit, rather than by day, the outcome was defined as prevalent weeks. Pneumonia by maternal report was considered to have occurred if there was a history of either fast breathing or chest in-drawing. Confirmed pneumonia was defined as an elevated respiratory rate at rest measured by the fieldworker using WHO/UNICEF Integrated Management of Childhood Illness guidelines.[5]

Sample size
This was done separately for each of the three cohorts and was based on percentage of days of diarrhea for each child by cohort and treatment arm. We assumed the percentage of days with diarrhea in HIV-infected children receiving vitamin A alone would be 4.4% (SD ± 0.9%); for those receiving vitamin A and zinc it would be 3.7% ± 0.9% (17% less than for those receiving vitamin
A alone); and for those receiving multiple micronutrients it would be 3.0%±0.9% (33% less than for those receiving vitamin A alone and 20% less than for those receiving vitamin A and zinc). For HIV-uninfected children we postulated the same differences between treatment groups but with lower diarrhea prevalence rates: 3.3%±0.9% (vitamin A alone); 2.8%±0.9% (vitamin A and zinc); and 2.2%±0.9% (multiple micronutrient group). To determine with a power of 0.8 and a two-sided significance level of 0.05 if these postulated differences existed, 26 children were required in each of the three arms of the HIV-infected cohort, and 45 children in each of the three arms of the two cohorts of HIV-uninfected children. We expected mortality, migration, and withdrawals to diminish days of observation by 50% in the HIV-infected cohort and 25% in the HIV-uninfected groups. Thus the total sample size required was 156 in the HIV-infected cohort and 180 children in each of the two cohorts of HIV-uninfected children.

Randomization–sequence generation
An allocation list was prepared using computer-generated random numbers and a block size of six. Assignment to the three treatment arms was done separately for three cohorts of children stratified by HIV status of child and mother: HIV-infected children and mothers; HIV-uninfected children of HIV-infected mothers; and HIV-uninfected children of HIV-uninfected mothers.

Randomization–allocation concealment and implementation
The manufacturer prepared numbered packs of tablets corresponding to the allocation list. Children enrolled in the study were assigned by a study physician to one of the three study cohorts after results of the HIV tests became available. The physician then allocated the next pack of tablets from the blocks assigned to that cohort to the participant.

Blinding
Investigators, study staff and participants were blind to the treatment assignments.

Study procedures
At enrollment study subjects had a physical examination and medical history taken by the study nurse. Weight was measured to a precision of 0.1 kg using an electronic digital scale and recumbent length to a precision of 0.1 cm using an infantometer. For determination of anthropometric centiles National Center for Health Statistics standards were used.[15] Mothers and children had a blood sample taken for determination of HIV infection status if their status was not already known and documented, and for determining haemoglobin concentration. A two-week supply of tablets was provided at enrolment, and the mothers instructed on how to administer them. A portable HemoCue system (Angelholm, Sweden) was used to test haemoglobin concentration. Hemoglobin assay (Nuclisens HIV-1 QT, Organon Teknika or Nuclisens EasyQ HIV-1, Biomerieux, Boxtel, The Netherlands). Maternal HIV status was determined using two ELISA tests (first Vironostika HIV-1 Microelsa system and then Uni-Form II plus O if the first test was positive, both Biomerieux) each of which had to be positive for HIV infection to be diagnosed. Hemoglobin determination was done at the clinic by study nurses using a portable HemoCue system (Angelholm, Sweden).

Statistical methods
Data were entered into an electronic data base using an optical form scanning system (TeleForm version 7.1 Cardiff, Vista CA, USA) and were analyzed using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA) and EpiInfo version 3.5.2 (Centers for Disease Control and Prevention, Atlanta, GA, USA). Analyses were done on a locked dataset using an analysis plan, and tests of significance, that were determined before the analyses were conducted. Analyses were initially conducted using coded treatment groups with the analysts blinded to the actual treatment. Analysis of all outcomes was on an intention-to-treat basis—all participants for whom there were observations on study outcomes were included in the analysis. In addition to comparing baseline characteristics between children in the treatment groups, we also examined features during study that could have confounded study outcome. These were rates of drop-out and death, proportion of missing information, dietary pattern, adherence to treatment, and intake of other vitamin and micronutrient preparations. Any baseline or during treatment characteristics that differed significantly between treatment arms was tested for its association with the study outcome using Spearman’s rank correlation test.

The primary outcome–percentage of days of diarrhea per child by cohort and treatment group was not normally distributed as determined by the Kolmogorov-Smirnov test, and a Kruskall-Wallis test was used to determine the overall significance of difference between treatment arms. For secondary outcomes and for baseline characteristics the significance of differences for continuous variables was tested using one-way ANOVA if the variable was normally distributed or the Kruskall-Wallis test if not normally distributed. Differences in proportions were tested with
the \( \chi^2 \) test. Comparisons between individual groups were made only if the overall group comparison found a significant difference.

To determine the effect size for the primary outcome, we determined the difference between medians, and the 95\% confidence intervals for those differences, using the binomial method.[18] All tests of differences or association were two-sided, and were considered significant if the P value was \( \leq 0.05 \).

We also tested for any bias in assignment to treatment cohort (on the assumption that blinding may not have been completely effective) using the Berger-Exner test.[19]

**RESULTS**

**Recruitment, patient flow, and numbers analyzed**

Study enrollment began in June 2003 and the last participant enrolled in October 2004. Patient observations were completed 31 January 2006. Three-hundred seventy-three children were enrolled in the study—32 HIV-infected children, 154 children without HIV infection born to HIV-infected mothers, and 187 children born to HIV-uninfected mothers (Figure 1). Thirty-seven children withdrew and one died before any home visits took place, leaving 335 children for whom information on outcomes was available and who were included in the analysis (Figure 1). One-hundred thirteen of these 335 children each received vitamin A alone or vitamin A plus zinc, and 109 of the children received multiple micronutrients. Ten of these 335 children never took the supplement but were included in this intention-to-treat analysis. Berger-Exner tests performed in each cohort separately showed no evidence of bias in assignment to treatment group. Controlling for treatment arm, the P-values for the partial correlation between percent days of diarrhea (the main outcome) and the remaining proportion of multivitamin tablets in the block at the time of random assignment to therapy was >0.23 in each of the three cohorts.

Twelve (3.6\%) of the 335 children with at least one home visit died during the study, including 8 (29\%) of the 28 children with HIV infection. An additional 88 (26.2\%) of the 333 children who had at least one home visit did not complete the study (Table 1). Fifty-seven children moved out of the area during the study. Reasons given for withdrawal in the other 31 children included lack of time by parent to participate (2 children), the child not liking the taste of the tablets (3 children), objections from grandparent or father (2 children) and unspecified reasons in 24 children. The median duration of enrollment in the study was 447 days and did not differ significantly between groups.

**Baseline data**

Baseline demographic characteristics of the treatment groups in the three cohorts did not significantly differ with the exception of weight-for-length in the group of HIV-uninfected children born to HIV-uninfected mothers (Table 1).

**Outcomes**

**Diarrheal morbidity** There was no significant difference between treatment groups in the primary outcome—percentage of days with diarrhea—in any of the three cohorts (Tables 2 and 3). The median percentage of days with diarrhea ranged from 3.4\% to 7.1\% in the three treatment arms in HIV-infected children, and from 1.8\% to 2.7\% in the treatment arms in the two cohorts of HIV-uninfected children. In all comparisons the 95\% CI for the differences between groups crossed zero (Table 3). There was no difference between treatment arms in any of the secondary outcome measures of diarrhea severity or frequency (Table 2). Children enrolled in the study had a median of 2 episodes of diarrhea while in the study. During 352 person-years of observation for the children in the study there were a total of

![Figure 1. Patient Flowchart](https://doi.org/10.1371/journal.pone.0000541.g001)
Table 1. Characteristics of 335 children by study cohort and treatment arm

| Characteristic                                      | HIV-infected children | HIV-uninfected children born to HIV-infected mothers | HIV-uninfected children born to HIV-uninfected mothers |
|-----------------------------------------------------|-----------------------|-----------------------------------------------------|-----------------------------------------------------|
|                                                     | Treatment group       | Treatment group                                     | Treatment group                                     |
|                                                     | Vitamin A (n = 8)      | Vitamin A + zinc (n = 9)                             | Vitamin A + zinc (n = 47)                             |
|                                                     | Multiple micronutrients (n = 11) | Multiple micronutrients (n = 46)                      | Multiple micronutrients (n = 52)                      |
|                                                     | P                     |                                                     |                                                     |
| Age at enrollment into study, months                | 5.5 (0.4)             | 5.4 (0.5)                                           | 5.5 (0.6)                                           | 5.6 (0.5)                                           | 0.372                       |
|                                                     | 5.4 (0.5)             | 5.5 (0.3)                                           | 5.5 (0.6)                                           | 5.6 (0.5)                                           | 0.372                       |
|                                                     | 5.4 (0.5)             | 5.5 (0.3)                                           | 5.5 (0.6)                                           | 5.6 (0.5)                                           | 0.372                       |
| Age at initiation of therapy, months                | 8.0 (1.8)             | 7.4 (1.0)                                           | 8.0 (1.3)                                           | 7.8 (1.3)                                           | 0.737                       |
|                                                     | 7.8 (1.3)             | 8.0 (1.3)                                           | 7.8 (1.3)                                           | 7.8 (1.3)                                           | 0.737                       |
|                                                     | 7.8 (1.3)             | 8.0 (1.3)                                           | 7.8 (1.3)                                           | 7.8 (1.3)                                           | 0.737                       |
| Male, n (%)                                         | 6 (75.0)              | 5 (55.6)                                            | 4 (36.4)                                            | 0.247                                               | 0.247                       |
|                                                     | 24 (49.0)             | 25 (53.2)                                           | 21 (45.7)                                           | 0.767                                               | 0.767                       |
|                                                     | 35 (62.5)             | 25 (43.9)                                           | 28 (53.8)                                           | 0.139                                               | 0.139                       |
| Piped or well water used for preparing feeds, n (%)  | 6 (85.7)              | 5 (83.3)                                            | 6 (75.0)                                            | 0.857                                               | 0.857                       |
|                                                     | 36 (76.6)             | 36 (80.0)                                           | 33 (71.7)                                           | 0.649                                               | 0.649                       |
|                                                     | 43 (82.7)             | 40 (70.2)                                           | 44 (88.0)                                           | 0.059                                               | 0.059                       |
| Anthropometry                                        |                       |                                                     |                                                     |                                                     |                            |
| Weight for age Z-score                              | −0.02 (1.3)           | −1.05 (1.3)                                         | −0.12 (1.6)                                         | 0.340                                               | 0.340                       |
|                                                     | 0.21 (1.2)            | 0.28 (1.2)                                         | 0.08 (1.18)                                         | 0.722                                               | 0.722                       |
|                                                     | 0.34 (1.21)           | 0.54 (1.00)                                         | 0.70 (1.17)                                         | 0.260                                               | 0.260                       |
| Length for age Z-score                              | −1.37 (0.8)           | −1.00 (1.4)                                         | −1.00 (1.19)                                         | 0.791                                               | 0.791                       |
|                                                     | −0.64 (0.82)          | −0.50 (0.98)                                         | −0.74 (1.09)                                         | 0.514                                               | 0.514                       |
|                                                     | −0.36 (0.87)          | −0.34 (1.02)                                         | −0.37 (0.89)                                         | 0.990                                               | 0.990                       |
| Weight for length Z-score                           | 0.80 (2.08)           | −0.03 (0.74)                                         | 0.51 (1.36)                                         | 0.535                                               | 0.535                       |
|                                                     | 0.87 (1.29)           | 0.86 (0.94)                                         | 0.74 (1.01)                                         | 0.842                                               | 0.842                       |
|                                                     | 0.61 (1.06)           | 1.00 (0.95)                                         | 1.10 (1.13)                                         | 0.051                                               | 0.051                       |
| Hemoglobin, g/dl                                    | 10.0 (1.4)            | 9.8 (0.7)                                           | 8.8 (2.5)                                           | 0.483                                               | 0.483                       |
|                                                     | 10.3 (1.3)            | 10.5 (1.3)                                          | 10.1 (1.1)                                          | 0.598                                               | 0.598                       |
|                                                     | 9.9 (1.2)             | 10.2 (1.1)                                          | 10.3 (1.2)                                          | 0.363                                               | 0.363                       |
| Hemoglobin, g/dl                                    | 21.2 (7.8)            | 1 (1.1)                                             | 3 (27.3)                                            | 0.653                                               | 0.653                       |
|                                                     | 10 (20.4)             | 12 (25.5)                                           | 14 (30.4)                                           | 0.532                                               | 0.532                       |
|                                                     | 15 (26.8)             | 14 (24.6)                                           | 17 (32.7)                                           | 0.624                                               | 0.624                       |
| Hemoglobin, g/dl                                    | 30.6 (107–536)        | 181 (62–485)                                        | 347 (49–527)                                        | 0.912                                               | 0.912                       |
|                                                     | 464 (318–510)         | 418 (255–478)                                       | 395 (270–501)                                       | 0.165                                               | 0.165                       |
|                                                     | 467 (270–515)         | 486 (342–530)                                       | 439 (309–529)                                       | 0.535                                               | 0.535                       |
| Hemoglobin, g/dl                                    | 31.0 (3.7–71.1)       | 13.0 (0.0–15.9)                                     | 2.0 (0.0–14.7)                                      | 0.967                                               | 0.967                       |
|                                                     | 4.7 (1.0–14.2)        | 7.7 (2.2–21.4)                                      | 5.5 (1.3–19.7)                                      | 0.502                                               | 0.502                       |
|                                                     | 42.0 (7.7–12.2)       | 4.6 (1.4–10.2)                                      | 2.3 (0.4–9.2)                                       | 0.651                                               | 0.651                       |
| Percent of study days not available, median (25th–75th percentiles) | 3.1 (0.3–7.1) | 1.3 (0.0–15.9)                                      | 2.0 (0.0–14.7)                                      | 0.967                                               | 0.967                       |
| Percent of study days supplement not given median (25th–75th percentiles) | 22.0 (14.6–29.0) | 11.6 (25–28.1)                                      | 33.7 (123–100)                                      | 0.073                                               | 0.073                       |
| Percent of study days for which recall period ≤ 7 days | 72.1 (56.5–79.1) | 69.6 (56.7–92.2)                                     | 76.8 (63.7–80.5)                                     | 0.858                                               | 0.858                       |

Values are mean (standard deviation) or n (%), unless noted. P values are for the overall group comparison using one-way ANOVA, Kruskall-Walliss or 2 x 3 x 2 test.

Information on water use was not available in the cohort of HIV-infected children for 1 child in the vitamin A group, 3 children in the vitamin A + zinc group, and 1 child in the multiple micronutrient group. In the cohort of HIV-uninfected children born to HIV-infected mothers, information was missing for 4 children in the vitamin A group and 2 children in the multiple micronutrient group. In the cohort of HIV-uninfected children born to HIV-uninfected mothers, information was missing for 4 children in the vitamin A group, and 2 children in the multiple micronutrient group.

As a Z-score of NCHS standards[15]

Hemoglobin values were not available in the cohort of HIV-infected children for 5 children in each of the three treatment groups. In the cohort of HIV-uninfected children born to HIV-infected mothers, hemoglobin determinations were not available for 26 children who received vitamin A, 28 children who received vitamin A + zinc, and 20 children who received multiple micronutrients. In the cohort of HIV-uninfected children born to HIV-uninfected mothers, hemoglobin measurements were not available for 34 children in the vitamin A group, 32 children in the vitamin A + zinc group, and 33 children in the multiple micronutrient group.

Days study drug was not given were determined during weekly home visits.

Excludes days after withdrawal of study subjects for which home visits were not permitted, lost to follow-up, or death.

doi:10.1371/journal.pone.0000541.t001
| Characteristic | HIV-infected children | HIV-uninfected children born to HIV-infected mothers | HIV-uninfected children born to HIV-uninfected mothers |
|---------------|-----------------------|----------------------------------------------------|-----------------------------------------------------|
|               | Treatment Group P     | Treatment Group P                                   | Treatment Group P                                    |
| Vitamin A     | (n = 8)               | Vitamin A + zinc (n = 9)                            | Vitamin A (n = 49)                                   |
| Multiple       | Vitamin A + zinc      | Multiple micronutrients (n = 11)                   | Multiple micronutrients (n = 46)                     |
| Primary outcome | Percentage of days with diarrhea per child | 3.4 (0.8–9.4)                                    | 7.1 (2.4–12.3)                                       |
|               |                       | 5.9 (1.5–16.1)                                     | 9 (81.8)                                             |
|               |                       | 0.668                                              | 0.891                                               |
| Secondary outcomes-diarrhea | Children who ever had diarrhea, n (%) | 7 (87.5)                                      | 8 (88.9)                                             |
|               |                       | 3 (33.3)                                           | 6 (54.5)                                             |
|               |                       | 0.388                                              | 0.790                                               |
|               | Diarrhea episodes per child | 2 (1–7)                                           | 3 (2–7)                                             |
|               |                       | 3 (2–5)                                            | 2 (1–4)                                             |
|               | Duration of diarrhea episode, days | 3.0 (2.3–5.6)                                    | 4.4 (3.1–5.5)                                       |
|               |                       | 6.3 (2.8–7.8)                                     | 3.0 (2.5–4.0)                                       |
|               | Children with diarrhea episodes ≥14 d, n (%) | 0                                               | 3 (33.3)                                           |
|               |                       | 3 (27.3)                                           | 3 (6.1)                                             |
|               | Children with >5 stools/day on worst day of diarrhea episode* | 3/7 (42.9)                                        | 4/8 (50.0)                                          |
|               |                       | 5/9 (55.6)                                         | 0.881                                               |
|               | Children who visited clinic for diarrhea, n (%) | 3 (37.5)                                       | 6 (66.7)                                             |
|               |                       | 9 (81.8)                                           | 0.136                                               |
| Secondary outcomes-respiratory illness | Percentage of weeks with upper respiratory symptoms | 12.4 (20.0–36.2)                                | 29.0 (10.1–50.0)                                    |
|               |                       | 23.7 (20.2–33.3)                                   | 13.1 (7.8–24.7)                                      |
|               | Children who ever had pneumonia by maternal report, n (%) | 3 (37.5)                                        | 4 (44.4)                                             |
|               |                       | 6 (54.5)                                           | 0.755                                               |
|               | Children who ever had pneumonia confirmed by measured respiratory rate, n (%) | 3 (37.5)                                        | 1 (11.1)                                           |
|               |                       | 4 (36.4)                                           | 0.371                                               |
| Other secondary outcomes | Died during study, N, (%) | 2 (25.0)                                       | 4 (44.4)                                             |
|               |                       | 2 (18.2)                                           | 0.418                                               |
|               | Admitted to hospital for any reason during study | 0                                                | 2 (22.2)                                           |
|               |                       | 4 (36.4)                                           | 0.162                                               |

Values are median (25th–75th centiles) or n (%). P values are for the overall group comparison using the Kruskall-Wallis test or 2 x 3 χ² test. 
*Denominator is number of study children who ever had diarrhea. 
doi:10.1371/journal.pone.0000541.t002
1115 episodes of diarrhea, or 3.2 per year of observation. Only 28 children (8.4%) had episodes of persistent diarrhea lasting >14 days, and 79 (23.6%) ever had blood in their stool.

**Respiratory disease morbidity** There were no differences between study groups in the median percentage of weeks with upper respiratory symptoms, which ranged from 13.1% to 16.6% in the three treatment groups in the two cohorts of children without HIV infection; or in the percentage of children who had pneumonia confirmed by measured respiratory rate, which ranged from 4.3% to 19.1% (Table 2).

**Combined comparison of all cohorts** When the three study cohorts were combined there were no significant differences in either the primary or secondary outcomes by supplement given (Table 4).

### Ancillary analyses

There was no effect of treatment when subjects 6–12 months or 12–24 months, or those less than 1.5 or 2.0 z scores of length-for-age, were analyzed separately.

Study subjects received supplements 77% of days they were enrolled in the study (Table 1), but there was no significant difference between groups in percentage of days supplement was taken. Among the participant characteristics during study that might have confounded study outcome the only significant differences were the median number of study weeks that study subjects were fed cereal, which differed between treatment groups in both the cohorts of HIV-infected children, and HIV-uninfected children born to HIV-infected mothers; and the clinic used by

### Table 3. Differences in median percentage of days of diarrhea by treatment group and cohort, and for the three cohorts combined.

| Treatment group comparison | HIV-infected children | HIV-uninfected children born to HIV-infected mothers | HIV-uninfected children born to HIV-uninfected mothers |
|----------------------------|-----------------------|-----------------------------------------------------|------------------------------------------------------|
| Vitamin A versus vitamin A plus zinc | −2.5 days (−8.8, 2.5) | −0.2 days (−1.3, 0.7) | 0.2 days (−0.6, 1.2) |
| Vitamin A versus multiple micronutrients | −1.9 days (−13.9, 2.8) | −0.2 days (−1.2, 0.7) | 0 days (−0.8, 1.1) |
| Vitamin A plus zinc versus multiple micronutrients | 0.1 days (−8.3, 7.1) | 0 days (−0.9, 1.2) | 0 days (−1.1, 0.8) |
| **Three cohorts combined** | | | |
| Vitamin A versus vitamin A plus zinc | 0 days (−0.8, 0.6) | 0 days (−0.5, 0.8) | 0 days (−0.8, 0.7) |

Values are the difference between groups in median prevalent days of diarrhea (95% CI for the difference). Differences between groups are estimated by calculating the median of all possible differences between patients in the groups being compared, rather than the arithmetic difference in the population median.

### Table 4. Outcomes of 335 children with at least one home visit by treatment arm for all three cohorts combined.

| Characteristic | Vitamin A (n = 113) | Vitamin A+ zinc (n = 113) | Multiple micronutrients (n = 109) | P |
|----------------|---------------------|---------------------------|-----------------------------------|----|
| **Diarrhea morbidity** | | | | |
| Percentage of days with diarrhea per child | 2.3 (0.8–4.5) | 2.4 (0.7–5.5) | 2.5 (0.8–5.4) | 0.935 |
| Children who ever had diarrhea, n (%) | 98 (86.7) | 92 (81.4) | 89 (81.7) | 0.484 |
| Children who ever had blood in stools, n (%) | 26 (23.0) | 26 (23.0) | 27 (24.8) | 0.939 |
| Diarrhea episodes per child | 2 (1–5) | 3 (1–4) | 2 (1–5) | 0.917 |
| Duration of diarrhea episodes, days | 3.0 (2.5–4.6) | 4.0 (2.7–5.0) | 4.0 (2.6–5.7) | 0.067 |
| Children who ever had diarrhea episodes ≥14 days, n (%) | 5 (4.4) | 11 (9.7) | 12 (11.0) | 0.168 |
| Children with >5 stools/day on worst day of diarrhea episode* | 40/96 (40.8) | 43/92 (46.7) | 43/89 (48.3) | 0.550 |
| Children who ever visited clinic for diarrhea, n (%) | 61 (54.0) | 48 (42.5) | 52 (47.7) | 0.223 |
| Children ever admitted to hospital with diarrhea: n (%) | 2 (1.8) | 4 (3.5) | 7 (6.4) | 0.195 |
| **Respiratory morbidity** | | | | |
| Percentage of weeks with upper respiratory illness signs per child | 15.4 (8.4–24.4) | 15.8 (8.0–26.1) | 15.7 (8.4–25.0) | 0.695 |
| Children who ever had pneumonia by maternal report, n (%) | 23 (20.4) | 30 (26.5) | 21 (19.3) | 0.366 |
| Children who ever had pneumonia confirmed by respiratory rate, n (%) | 17 (15.0) | 20 (17.7) | 11 (10.1) | 0.261 |
| **Other outcomes** | | | | |
| Died during study, n (%) | 3 (2.7) | 6 (5.3) | 3 (2.8) | 0.478 |
| Admitted to hospital for any reason during study | 4 (3.5) | 10 (8.8) | 11 (10.1) | 0.141 |

Values are median (25th–75th centiles) or n (%). P values are for the overall group comparison using the Kruskall-Wallis test or 2 x 3 x 2 test.

*Denominator is number of study children who ever had diarrhea.

[1] doi:10.1371/journal.pone.0000541.t003

[2] doi:10.1371/journal.pone.0000541.t004
HIV-infected children. Neither of these variables was associated with days of diarrhea, however, and thus we did not adjust for them in the analyses of outcomes.

**Adverse Effects**

Vomiting in the 30 minutes after administration of the supplement was witnessed by the field worker 7 times with vitamin A and zinc, and once each following administration of vitamin A and multiple micronutrients.

**DISCUSSION**

**Interpretation**

In this study neither zinc combined with vitamin A, nor zinc and vitamin A combined with other micronutrients, reduced diarrhea and respiratory disease morbidity in three cohorts of children 6–24 months of age in rural South Africa–HIV-infected children, HIV-uninfected children born to HIV-infected mothers, or children born to HIV-infected mothers. Enrollment of children with HIV infection was much smaller than the proposed sample size in the study protocol, thus limiting any conclusions about efficacy in this cohort. But enrollment in the other two cohorts was approximately what was planned, and conclusions on findings in these cohorts are thus robust.

**Generalizability**

The findings of this study are in contrast to the preponderance of findings from previous studies.[6] A meta-analysis of seven studies of continuous supplementation with zinc found a 25% reduction in diarrhea prevalence, and 18% reduction in diarrhea incidence,[6] and in the four studies included in the meta-analysis that reported the effect of zinc on pneumonia there was a 41% decrease in pneumonia incidence.[6]

What differences in study population, study design or supplement formulation might have accounted for the lack of effect of zinc or micronutrient supplementation on diarrhea or respiratory morbidity in this study when compared to previous studies? Children enrolled in this trial had better anthropometric indices than those reported on in most previous studies. Despite the food insecurity and poverty in the community, only 6.4% of children in this study were <2 z scores for length-for-age, compared to 32–100% of children in studies included in the meta-analysis that reported the impact of zinc on pneumonia there was a 41% decrease in pneumonia incidence.[6]

What differences in study population, study design or supplement formulation might have accounted for the lack of effect of zinc or micronutrient supplementation on diarrhea or respiratory morbidity in this study when compared to previous studies? Children enrolled in this trial had better anthropometric indices than those reported on in most previous studies. Despite the food insecurity and poverty in the community, only 6.4% of children in this study were <2 z scores for length-for-age, compared to 32–100% of children in studies included in the meta-analysis that reported the impact of zinc on pneumonia there was a 41% decrease in pneumonia incidence.[6]

What differences in study population, study design or supplement formulation might have accounted for the lack of effect of zinc or micronutrient supplementation on diarrhea or respiratory morbidity in this study when compared to previous studies? Children enrolled in this trial had better anthropometric indices than those reported on in most previous studies. Despite the food insecurity and poverty in the community, only 6.4% of children in this study were <2 z scores for length-for-age, compared to 32–100% of children in studies included in the meta-analysis that reported the impact of zinc on pneumonia there was a 41% decrease in pneumonia incidence.[6]

What differences in study population, study design or supplement formulation might have accounted for the lack of effect of zinc or micronutrient supplementation on diarrhea or respiratory morbidity in this study when compared to previous studies? Children enrolled in this trial had better anthropometric indices than those reported on in most previous studies. Despite the food insecurity and poverty in the community, only 6.4% of children in this study were <2 z scores for length-for-age, compared to 32–100% of children in studies included in the meta-analysis that reported the impact of zinc on pneumonia there was a 41% decrease in pneumonia incidence.[6]

What differences in study population, study design or supplement formulation might have accounted for the lack of effect of zinc or micronutrient supplementation on diarrhea or respiratory morbidity in this study when compared to previous studies? Children enrolled in this trial had better anthropometric indices than those reported on in most previous studies. Despite the food insecurity and poverty in the community, only 6.4% of children in this study were <2 z scores for length-for-age, compared to 32–100% of children in studies included in the meta-analysis that reported the impact of zinc on pneumonia there was a 41% decrease in pneumonia incidence.[6]

What differences in study population, study design or supplement formulation might have accounted for the lack of effect of zinc or micronutrient supplementation on diarrhea or respiratory morbidity in this study when compared to previous studies? Children enrolled in this trial had better anthropometric indices than those reported on in most previous studies. Despite the food insecurity and poverty in the community, only 6.4% of children in this study were <2 z scores for length-for-age, compared to 32–100% of children in studies included in the meta-analysis that reported the impact of zinc on pneumonia there was a 41% decrease in pneumonia incidence.[6]

What differences in study population, study design or supplement formulation might have accounted for the lack of effect of zinc or micronutrient supplementation on diarrhea or respiratory morbidity in this study when compared to previous studies? Children enrolled in this trial had better anthropometric indices than those reported on in most previous studies. Despite the food insecurity and poverty in the community, only 6.4% of children in this study were <2 z scores for length-for-age, compared to 32–100% of children in studies included in the meta-analysis that reported the impact of zinc on pneumonia there was a 41% decrease in pneumonia incidence.[6]

What differences in study population, study design or supplement formulation might have accounted for the lack of effect of zinc or micronutrient supplementation on diarrhea or respiratory morbidity in this study when compared to previous studies? Children enrolled in this trial had better anthropometric indices than those reported on in most previous studies. Despite the food insecurity and poverty in the community, only 6.4% of children in this study were <2 z scores for length-for-age, compared to 32–100% of children in studies included in the meta-analysis that reported the impact of zinc on pneumonia there was a 41% decrease in pneumonia incidence.[6]
### Table 5. Studies of zinc supplementation, either alone or with other micronutrients, for prevention of diarrhea and respiratory illness in African children.

| Author       | Country       | Date | Study population | Study method                  | Primary outcome | Intervention A | Frequency and duration | Intervention B | Frequency and Duration | Nutritional status | Nutritional status | Effect of intervention on diarrhea | Effect of intervention on respiratory illness |
|--------------|---------------|------|------------------|--------------------------------|-----------------|-----------------|------------------------|-----------------|------------------------|----------------------|----------------------|--------------------------------------|------------------------------------------------|
| Umetsu[7]    | Ethiopia      | 2000 | Breast-fed infants 6–12 m | Double-blind RCT. Daily home visits | Linear growth | 10 mg zinc sulphate. 45 stunted children <2 z score length-for-age; 45 age and sex matched non-stunted children | Daily except Sunday for six months | Placebo. 45 stunted children <2 z score length-for-age; 45 age and sex matched non-stunted children | Daily except Sunday for six months | Z-scores for stunted zinc group: −2.74 for length-for-age; −2.46 for weight-for-age; −0.48 for weight-for-length. For non-stunted group: −0.70 for length-for-age; −1.35 for weight-for-age; −1.00 for weight-for-length. | For stunted group, 13 episodes (0.6 episodes per child per year) in zinc-supplemented group vs. 40 episodes (1.7 episodes per year) in placebo group (P<0.001). For non-stunted group, 14 episodes (0.6 episodes per year) in zinc group, 21 episodes (0.9 episodes per year) in placebo group (P=NS). | For stunted group, 15 episodes of cough (0.7 episodes per child per year) in zinc-supplemented group vs. 30 episodes (1.3 episodes per year) in placebo group (P<0.005). For non-stunted group, 12 episodes (0.3 episodes per year) in zinc group, 21 episodes (0.9 episodes per year) in placebo group (P=NS). |
| Müller[8]    | Burkina Faso  | 2001 | Children 6–31 m from DSS | Double-blind RCT. Home visits 2 per week | Reduction in malaria incidence | 12.5 mg zinc sulphate. 341 children | Daily except Sunday for six months | Placebo. 344 children | Daily except Sunday for six months | Reported jointly for zinc and placebo groups: 36.3% <2 z score height-for-age; 24.6% <2 z score weight-for-height | 1.8% days with diarrhea in zinc group, 2.0% in placebo group. RR 0.87 (95% CI 0.79 to 0.95) | 2.0% days with cough in zinc group, 1.9% in placebo group. RR 1.05 (95% CI 0.97 to 1.15) |
| Makonnen[42] | Lesotho       | 2003 | Malnourished children 6–60 months identified in hospital and followed at home after discharge | Double-blind RCT. Home visits after discharge from hospital | Not specified | 10 mg zinc sulphate in 150 children | Daily for three months after hospital discharge | Placebo in 150 children | Daily for three months after hospital discharge | 91% <2 z score weight-for-age | 87% <2 z score weight-for-age | At 90 days, prevalence of diarrhea in zinc-supplemented group was 2.9%; in placebo group was 16.9% (95% CI for difference reported as −32 to −15). | At 90 days, prevalence of acute respiratory infection in zinc-supplemented group was 2.9%, in placebo group 38.8% (95% CI for difference = 45 to −26). |
| Smuts[40]    | South Africa  | 2006 | Infants 6–12 m    | Double-blind RCT. Weekly home visits | Change in weight-for-age status | 10 mg zinc sulphate in 49 children or six months | Intervention A: 1 daily allowance of multiple micronutrients given daily to 49 children or six months | Placebo in 150 children | Intervention B: 2 x daily allowance of multiple micronutrients given weekly, with placebo on other days, given to 46 children for six months | Intervention C: 10 mg elemental iron given daily to 49 children for six months | For total study population, 1.6% <2 z scores for weight-for-age; 0% <2 z scores for weight-for-length | Prevalent days of diarrhea were 20.9% in zinc group, 22.2% in daily micronutrient group, 21.1% in weekly micronutrient group, and 17.9% in daily iron group (P=NS) | Prevalent days of upper respiratory illness were 9.0% in the placebo group, 6.8% in the daily micronutrient group, 8.7% with the weekly micronutrient group, and 7.9% in the daily iron group (P=NS) |
| Boba[41]     | South Africa  | 2006 | HIV infected children 6–60 m not on ART | Double-blind RCT. 7 clinic visits during 6 month supplementation period; 1 visit 3 months after supplementation ended | Change in plasma HIV-1 RNA | 10 mg zinc sulphate to 46 children | Daily for six months | Placebo to 50 children | Daily for six months | Height-for-age z score: −1.5 Weight-for-height z score: −0.05 | In zinc group diarrhea prevalence 6.7% at 360 scheduled clinic visits, 7.4% at 407 total clinic visit in placebo group rates 105% and 14.5% respectively (P<0.001 by logistic regression for all events during all visits). | In zinc group pneumonia prevalence 10.8% at 360 scheduled clinic visits, 14% at 407 total clinic visit, in placebo group rates 12.7% and 18.6% respectively (P=0.07 by logistic regression for all events during all visits). Rates of upper respiratory infection and ear infection also did not differ significantly. |

**doi:** 10.1371/journal.pone.0000541.t005
diarrhea prevalence from 37% in the placebo to 3% in the zinc-supplemented group, and a reduction in acute respiratory infection from 39% to 3%.[42] A study of multiple micronutrient supplementation in South Africa did not find an effect of a zinc-containing micronutrient mixture on diarrhea morbidity despite very high rates of diarrhea prevalence.[40] A study in children in South Africa infected with HIV who were not on antiretroviral therapy found a reduction in diarrhea prevalence during scheduled or unscheduled clinic visits.[41] A recent large study from Tanzania found no effect of zinc supplementation on overall mortality, or diarrhea-related mortality.[43]

Overall evidence
What are the policy implications of this study? Because of the heterogeneity of different populations of children in developing countries and the heterogeneity of the studies of zinc that have been conducted to date, generalizing from any single study is problematic. This study had as its outcomes the efficacy of zinc or multiple micronutrient supplementation as primary prophylaxis of diarrhea and respiratory morbidity. Neither supplement was effective for either indication.

The study was conducted in children that were less severely stunted than in most previous micronutrient supplementation studies, and who may have benefited from recent efforts to fortify staple food with micronutrients. But it is still a population which has a high burden of ill-health, with an infant mortality rate of 68 per thousand and a child mortality ratio of 98 per thousand.[44] The findings of this study, along with a previously reported study of micronutrient supplementation conducted elsewhere in South Africa that did not show efficacy,[40] do not provide support for the prophylactic use of zinc or multiple micronutrients to reduce diarrhea or respiratory morbidity in the general population of South African children.

SUPPORTING INFORMATION

Checklist S1 CONSORT Checklist
Found at: doi:10.1371/journal.pone.0000541.s001 (0.05 MB DOC)

Protocol S1 Trial Protocol
Found at: doi:10.1371/journal.pone.0000541.s002 (0.41 MB DOC)

ACKNOWLEDGMENTS
We thank the community of Umkanyakude for their support of the study; the mothers, children and families that participated; the nurses, supervisors and field staff for their devotion to and hard work; Nigel Rollins for assistance in conceptualization of the study, proposal and protocol development, and initial study implementation; Porzia Mutevedzi and Nathalie Graham for assistance with laboratory studies; Cookie Govender and George Irving for assistance with data entry, and Mario Chen-Mok for advice on statistical methods.

Author Contributions
Principal investigator for the study: MLB. Served as Project Directors: JVBdK KAL. Supervised the field work for the study: NM. Conducted the laboratory studies: MM HW IE. Designed the study: MLB AT. Wrote the initial study protocol: MLB JVdB. Revised the study protocol: KAL JVBdB MLB. Designed the analysis plan and conducted the analysis: JVBdB MLB. Drafted the manuscript: MLB KAL JVBdB. Critically reviewed and approved the manuscript: all authors.

REFERENCES

1. Vitamin/mineral deficiencies. A global progress report The Micronutrient Initiative. (Accessed June 29,2004 at http://www.micronutrient.org/reports/Full_e.pdf.).
2. Labadarios D, Steyn NP, Maunde E, MacIntyre U, Gerick G, et al. (2003) The National Food Consumption Survey (NFCS): South Africa, 1999. Public Health Nutr 6: 533–43.
3. Mostert D, Steyn NP, Temple NJ, Olwagen R (2005) Dietary intake of pregnant women and their infants in a poor black South African community. Curarionis 28: 12–9.
4. Fischer Walker C, Black RE (2004) Zinc and the risk for infectious disease. Anna Rev Nutr 24: 253–75.
5. Technical updates of the guidelines on Integrated Management of Childhood Illness (IMCI): evidence and recommendations for further adaptations World Health Organization. (Accessed June 29,2005 at http://www.who.int/child-adolescent-health/New_Publishations/IMCI/ISBN_92_4_159348_2.pdf.).
6. Bhutta ZA, Black RE, Brown KH, Gardner JM, Gore S, et al. (1999) Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials. Zinc Investigators’ Collaborative Group. J Pediatr 135: 689–97.
7. Umeta M, West CE, Haidar J, Deurenberg P, Hautvast JG (2000) Zinc supplementation and stunted infants in Ethiopia: a randomised controlled trial. Lancet 355: 2021–6.
8. Muller O, Becher H, van Zwerden AB, Ye Y, Dhalo DA, et al. (2001) Effect of zinc supplementation on malaria and other causes of morbidity in west African children: randomised double blind placebo controlled trial. BMJ 322: 1567.
9. The state of the world’s children UNICEF. (Accessed June 30,2005 at http://www.unicef.org/sos06/pdfs/sos06_fullreport.pdf.).
10. National HIV and syphilis prevalence survey South Africa 2005 South Africa, Department of Health. (Accessed August 6,2006 at http://www.doh.gov.za/docs/reports/2005/biv.pdf.).
11. Bailey RC, Kamenga MC, Nsuami MJ, Nieburg P, St Louis ME (1999) Growth
12. A profile of KwaZulu-Natal: demographics, poverty, inequality and unemployment P涉及研究. (Accessed June 30,2005 at http://www.eisenberg.com/provide/documents/BP2003_1_5%20Demographics%20KZ.pdf.).
13. Bland RM, Rollins NC, Contousidis A, Covadonga HM (2002) Breastfeeding practices in an area of high HIV prevalence in rural South Africa. Acta Paediatr 91: 704–11.
14. Faber M (2005) Complementary foods consumed by 6-12-month-old rural infants in South Africa are inadequate in micronutrients. Public Health Nutr 8: 373–81.
15. Hamlill PV, Drizel TA, Johnson CL, Reed RB, Roche AF, et al. (1979) Physical growth: National Center for Health Statistics percentiles. Am J Clin Nutr 32: 667–29.
16. Lock G (2003) The foodLET vehicle designed for and used in the IRS I intervention. Food Nutr Bull 24: S16–9.
17. Kaushali S, Rollins N, Van den Broek J (2004) Local beliefs about childhood diarrhoea: importance for healthcare and research. J Trop Pediatr 50: 82–9.
18. Gardner MJ, Alman DG (1989) Statistics with confidence. Confidence intervals and statistical guidelines. London: British Medical Journal.
19. Berger VW, Eamer DV (1999) Detecting selection bias in randomized clinical trials. Control Clin Trials 20: 319–27.
20. Ruel MT, Rivera JA, Santizo MC, Lommerdal B, Brown KH (1997) Impact of zinc supplementation on morbidity from diarrhea and respiratory infections among rural Guatemalan children. Pediatrics 99: 808–13.
21. Basqui AH, Zamaan K, Persson LA, El Arifeen S, Yunus M, et al. (2003) Simultaneous weekly supplementation of iron and zinc is associated with lower morbidity due to diarrhea and acute lower respiratory infection in Bangladeshi infants. J Nutr 133: 4150–7.
22. Ninh NX, Thäsen JP, Collette L, Gerard G, Khoi HH, et al. (1996) Zinc supplementation increases growth and circulating insulin-like growth factor I (IGF-I) in growth-retarded Vietnamese children. Am J Clin Nutr 63: 514–9.
23. Monds Gardner J, Witter MM, Randameth ID (1996) Zinc supplementation: effects on the growth and morbidity of undernourished Jamaican children. Eur J Clin Nutr 52: 34–9.
24. Roy SK, Tomkins AM, Haider R, Behren RH, Akramuzzaman SM, et al. (1999) Impact of zinc supplementation on subsequent growth and morbidity in Bangladeshi children with acute diarrhoea. Eur J Clin Nutr 53: 529–34.
25. Sur D, Gupta DN, Mondal SK, Ghosh S, Manna B, et al. (2003) Impact of zinc supplementation on diarrheal morbidity and growth pattern of low birth weight infants in Kolkata, India, a randomized, double-blind, placebo-controlled, community-based study. Pediatres 112: 1327–32.
26. Long KZ, Montoya Y, Hertzmark E, Santos JL, Rosado JL (2006) A double-blind, randomized, clinical trial of the effect of vitamin A and zinc supplementation on diarrheal disease and respiratory tract infections in children in Mexico City, Mexico. Am J Clin Nutr 83: 693–700.

27. Sazawal S, Black RE, Bhan MK, Jalla S, Sinha A, et al. (1997) Efficacy of zinc supplementation in reducing the incidence and prevalence of acute diarrhea—a community-based, double-blind, controlled trial. Am J Clin Nutr 66: 413–8.

28. Penny ME, Marin RM, Duran A, Peerson JM, Lanata CF, et al. (2004) Randomized controlled trial of the effect of daily supplementation with zinc or multiple micronutrients on the morbidity, growth, and micronutrient status of young Peruvian children. Am J Clin Nutr 79: 457–65.

29. Rosado JL, Lopez P, Munez E, Martinez H, Allen LH (1997) Zinc supplementation reduced morbidity, but neither zinc nor iron supplementation affected growth or body composition of Mexican preschoolers. Am J Clin Nutr 65: 13–9.

30. Coldham C, Ross D, Quigley M, Segura Z, Chandramohan D (2000) Prospective validation of a standardized questionnaire for estimating childhood mortality and morbidity due to pneumonia and diarrhoea. Trop Med Int Health 5: 134–44.

31. Smuts CM, Lombard CJ, Benade AJ, Dhansay MA, Berger J, et al. (2005) Efficacy of a foodlet-based multiple micronutrient supplement for preventing growth faltering, anemia, and micronutrient deficiency of infants: the four country IRIS trial pooled data analysis. J Nutr 135: 631S–8S.

32. Fawzi WW, Chalmers TC, Herrera MG, Mosteller F (1993) Vitamin A supplementation and child mortality. A meta-analysis. JAMA 269: 898–903.

33. Vitamin A supplementation and child morbidity and mortality in developing countries United Nations University Press. (Accessed July 7, 1994 at http://www.unu.edu/unupress/food/6F15e.c/1F154E04.htm#Vitamin%20A%20supplementation%20and%20child%20morbidity%20and%20mortality%20in%20developing%20countries.).

34. Regulations relating to the fortification of certain foodstuffs Ministry of Health South Africa. (Accessed July 7, 2003 at http://www.doh.gov.za/docs/regulations/2003/fortification.html.).

35. de Roman Dl, Salazar M, Hambidge KM, Penny ME, Peerson JM, et al. (2005) Longitudinal measurements of zinc absorption in Peruvian children consuming wheat products fortified with iron only or iron and 1 of 2 amounts of zinc. Am J Clin Nutr 81: 637–47.

36. Faber M, Kvalvig JD, Lombard CJ, Benade AJ (2005) Effect of a fortified maize-meal porridge on anemia, micronutrient status, and motor development of infants. Am J Clin Nutr 82: 1032–9.

37. Tielsch JM, Khlaty SK, Stouttus RJ, Katz J, LeClerq SC, et al. (2006) Effect of routine prophylactic supplementation with iron and folic acid on preschool child mortality in southern Nepal: community-based, cluster-randomised, placebo-controlled trial. Lancet 367: 144–52.

38. Lopez de Romana G, Cusirramenses S, Lopez de Romana D, Gross R (2005) Efficacy of multiple micronutrient supplementation for improving anemia, micronutrient status, growth, and morbidity of Peruvian infants. J Nutr 135: 648S–52.

39. Untoro J, Karyadi E, Wibowo L, Erhardt MW, Gross R (2005) Multiple micronutrient supplements improve micronutrient status and anemia but not growth and morbidity of Indonesian infants: a randomized, double-blind, placebo-controlled trial. J Nutr 135: 638S–45.

40. Smuts CM, Dhansay MA, Faber M, van Stuijvenberg ME, Swanevelder S, et al. (2005) Efficacy of multiple micronutrient supplementation for improving anemia, micronutrient status, and growth in South African infants. J Nutr 135: 651S–52.

41. Bobat R, Coovadia H, Stephen C, Ndoo KL, McKerrow N, et al. (2005) Safety and efficacy of zinc supplementation for children with HIV-1 infection in South Africa: a randomised double-blind placebo-controlled trial. Lancet 366: 1892–7.

42. Makonnen B, Vorster A, Joubert B (2003) A randomized controlled study of the impact of dietary zinc supplementation in the management of children with protein-energy malnutrition in Lesotho: I. mortality and morbidity. J Trop Pediatr 49: 340–47.

43. Sazawal S, Black RE, Raman M, Chwaya HM, Dutta A, et al. (2007) Effect of zinc supplementation on mortality in children aged 1–48 months: a community-based randomised placebo-controlled trial. Lancet 369: 927–34.

44. Garrab A, Jaffar S, Knight S, Bradshaw D, Bennish ML (2006) Rates and causes of child mortality in an area of high HIV prevalence in rural South Africa. Trop Med Int Health 11: 1841–8.